Transcatheter Aortic Valve Replacement for Left Ventricular Assist Device–Induced Aortic Insufficiency

SURGICAL AORTIC VALVE replacement historically has been the standard of care for patients with severe, symptomatic aortic stenosis. However, up to one-third of patients with symptomatic aortic stenosis are not surgical candidates because of medical comorbidities, left ventricular dysfunction, or advanced age.1 In the past, inoperable patients had received medical management with poor outcomes, highlighting the need for a different intervention. Transcatheter aortic valve replacement (TAVR) first gained widespread attention in 2002, when Cribier et al implanted the first valve in a human recipient.2 Since then, approximately 200,000 patients have undergone the procedure to treat native valve aortic stenosis.